The Experts below are selected from a list of 118455 Experts worldwide ranked by ideXlab platform
Chi-wai Kan - One of the best experts on this subject based on the ideXlab platform.
-
effect of co Laser Treatment on the fabric hand of cotton and cotton polyester blended fabric
Polymers, 2017Co-Authors: On-na Hung, Chi-wai KanAbstract:This paper compares the impact of Laser Treatment on cotton and cotton/polyester blended fabric hand properties, using the PhabrOmeter system. Five fabric hand properties, namely, stiffness, smoothness, softness, wrinkle recovery rate, and drapability, were obtained, and it was proven that Laser Treatment could be successfully used to change the fabric hand. In the case of pure cotton woven fabrics, the fabrics were found to have better drapability and wrinkle recovery after Laser Treatment. In cotton/polyester blended fabrics, stiffness was found to be relatively higher after Laser irradiation.
-
Effect of CO2 Laser Treatment on the Fabric Hand of Cotton and Cotton/Polyester Blended Fabric
MDPI AG, 2017Co-Authors: On-na Hung, Chi-wai KanAbstract:This paper compares the impact of Laser Treatment on cotton and cotton/polyester blended fabric hand properties, using the PhabrOmeter system. Five fabric hand properties, namely, stiffness, smoothness, softness, wrinkle recovery rate, and drapability, were obtained, and it was proven that Laser Treatment could be successfully used to change the fabric hand. In the case of pure cotton woven fabrics, the fabrics were found to have better drapability and wrinkle recovery after Laser Treatment. In cotton/polyester blended fabrics, stiffness was found to be relatively higher after Laser irradiation
M J Elman - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal ranibizumab for diabetic macular edema with prompt versus deferred Laser Treatment 5 year randomized trial results
Ophthalmology, 2015Co-Authors: M J Elman, Christina J Flaxel, Adam R Glassman, Allison R Ayala, David J. Browning, Lee M. Jampol, Neil M Bressler, Thomas W StoneAbstract:Objective To report the 3-year follow-up results within a previously reported randomized trial evaluating prompt versus deferred (for ≥24 weeks) focal/grid Laser Treatment in eyes treated with intravitreal 0.5 mg ranibizumab for diabetic macular edema (DME). Design Multicenter, randomized clinical trial. Participants Three hundred sixty-one participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods Ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and random assignment to prompt or deferred (≥24 weeks) focal/grid Laser Treatment. Main Outcome Measures Best-corrected visual acuity and safety at the 156-week (3-year) visit. Results The estimated mean change in visual acuity letter score from baseline through the 3-year visit was 2.9 letters more (9.7 vs. 6.8 letters; mean difference, 2.9 letters; 95% confidence interval, 0.4–5.4 letters; P = 0.02) in the deferral group compared with the prompt Laser Treatment group. In the prompt Laser Treatment group and deferral group, respectively, the percentage of eyes with a ≥10-letter gain/loss was 42% and 56% ( P = 0.02), whereas the respective percentage of eyes with a ≥10-letter gain/loss was 10% and 5% ( P = 0.12). Up to the 3-year visit, the median numbers of injections were 12 and 15 in the prompt and deferral groups, respectively ( P = 0.007), including 1 and 2 injections, respectively, from the 2-year up to the 3-year visit. At the 3-year visit, the percentages of eyes with central subfield thickness of 250 μm or more on time-domain optical coherence tomography were 36% in both groups ( P = 0.90). In the deferral group, 54% did not receive Laser Treatment during the trial. Systemic adverse events seemed to be similar in the 2 groups. Conclusions These 3-year results suggest that focal/grid Laser Treatment at the initiation of intravitreal ranibizumab is no better, and possibly worse, for vision outcomes than deferring Laser Treatment for 24 weeks or more in eyes with DME involving the fovea and with vision impairment. Some of the observed differences in visual acuity at 3 years may be related to fewer cumulative ranibizumab injections during follow-up in the prompt Laser Treatment group. Follow-up through 5 years continues. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.
-
intravitreal ranibizumab for diabetic macular edema with prompt versus deferred Laser Treatment
Ophthalmology, 2012Co-Authors: M J Elman, Haijing Qin, Raj K Maturi, Adam R Glassman, Frederick L Ferris, Lloyd Paul Aiello, Neil M Bressler, Roy W Beck, Michele MeliaAbstract:Objective To report the 3-year follow-up results within a previously reported randomized trial evaluating prompt versus deferred (for ≥24 weeks) focal/grid Laser Treatment in eyes treated with intravitreal 0.5 mg ranibizumab for diabetic macular edema (DME). Design Multicenter, randomized clinical trial. Participants Three hundred sixty-one participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods Ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and random assignment to prompt or deferred (≥24 weeks) focal/grid Laser Treatment. Main Outcome Measures Best-corrected visual acuity and safety at the 156-week (3-year) visit. Results The estimated mean change in visual acuity letter score from baseline through the 3-year visit was 2.9 letters more (9.7 vs. 6.8 letters; mean difference, 2.9 letters; 95% confidence interval, 0.4–5.4 letters; P = 0.02) in the deferral group compared with the prompt Laser Treatment group. In the prompt Laser Treatment group and deferral group, respectively, the percentage of eyes with a ≥10-letter gain/loss was 42% and 56% ( P = 0.02), whereas the respective percentage of eyes with a ≥10-letter gain/loss was 10% and 5% ( P = 0.12). Up to the 3-year visit, the median numbers of injections were 12 and 15 in the prompt and deferral groups, respectively ( P = 0.007), including 1 and 2 injections, respectively, from the 2-year up to the 3-year visit. At the 3-year visit, the percentages of eyes with central subfield thickness of 250 μm or more on time-domain optical coherence tomography were 36% in both groups ( P = 0.90). In the deferral group, 54% did not receive Laser Treatment during the trial. Systemic adverse events seemed to be similar in the 2 groups. Conclusions These 3-year results suggest that focal/grid Laser Treatment at the initiation of intravitreal ranibizumab is no better, and possibly worse, for vision outcomes than deferring Laser Treatment for 24 weeks or more in eyes with DME involving the fovea and with vision impairment. Some of the observed differences in visual acuity at 3 years may be related to fewer cumulative ranibizumab injections during follow-up in the prompt Laser Treatment group. Follow-up through 5 years continues. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.
C W Kan - One of the best experts on this subject based on the ideXlab platform.
-
Effect of CO2 Laser Treatment on the fabric hand of cotton and cotton/polyester blended fabric
'MDPI AG', 2017Co-Authors: On Hung, C W KanAbstract:This paper compares the impact of Laser Treatment on cotton and cotton/polyester blended fabric hand properties, using the PhabrOmeter system. Five fabric hand properties, namely, stiffness, smoothness, softness, wrinkle recovery rate, and drapability, were obtained, and it was proven that Laser Treatment could be successfully used to change the fabric hand. In the case of pure cotton woven fabrics, the fabrics were found to have better drapability and wrinkle recovery after Laser Treatment. In cotton/polyester blended fabrics, stiffness was found to be relatively higher after Laser irradiation.Institute of Textiles and Clothing201803 bcm
-
Effects of Laser Treatment on fabric characteristics and performance
ICE Publishing, 2015Co-Authors: C W Kan, Yl Lam, Yt SiuAbstract:In most of the applications, textiles require specific surface preparation to control designated categories of fabric performance – for example, dye uptake and retention, adhesion and wettability – or various organoleptic properties specific to the targeted end use of the fabric. There are several methods available to apply patterns and improve color control and retention on a fabric. Among the various methods for modification of surfaces of synthetic or natural fibers, Laser Treatment facilitating the fabric dyeing and finishing has found increasingly broad applications in the past few years. This study examined the effects of Laser Treatment on fabric surface in the context of changes in organoleptic fabric properties, including shape and dimensions retention, deformability, shape conformation or drapeability and other properties commonly considered as ‘hand feel’. One cotton fabric and two polyester/cotton blended fabrics were treated with Laser and evaluated by the Kawabata Evaluation System for Fabric (KES-F) and by PhabrOmeter, which were used to test the hand feel value of the fabric. It was found through this work that the fabric's hand feel decreases with increase of pixel resolution and the energy density associated with the Laser power output and time of fabric exposure to Laser Treatment.Institute of Textiles and Clothin
-
co2 Laser Treatment as a clean process for treating denim fabric
Journal of Cleaner Production, 2014Co-Authors: C W KanAbstract:Abstract In this study, a carbon dioxide (CO 2 ) Laser was used for the colour-fading Treatment of denim fabrics. Two types of denim fabrics were Laser-treated: one was manufactured with low-twist yarn spun by torque-free ring-spinning technology, and the other was manufactured by conventional ring-spun yarn. Commercially available torque-free ring-spun cotton yarn was used to manufacture the denim fabrics. For comparison, one specimen of denim fabric featured torque-free ring-spun yarn in the warp direction and conventional ring-spun yarn in the weft direction, whereas another specimen featured conventional ring-spun yarn in both the warp and weft directions. The warp yarn of both specimens was dyed by the same indigo dyeing process. The denim fabric samples were treated with a CO 2 Laser under the same conditions, and two Laser processing parameters, namely, (i) resolution and (ii) pixel time, were used to adjust the Laser power. After Laser Treatment, the colour properties (reflectance and colour parameters of the fabrics, such as the K/S value (the Kubelka-Munk function was used to represent the colour yield of the fabrics, where K is absorption and S is scattering) and CIE L * a * b * values) and dimensional stability of the denim samples were compared, and the results were analysed thoroughly. In addition, the colour-fading effect induced by CO 2 Laser Treatment was compared with that induced by conventional cellulase Treatment. Experimental results revealed that CO 2 Laser Treatment is an effective alternative means of producing the colour-fading effect in denim fabrics if the processing parameters can be carefully controlled.
Andrea Amaroli - One of the best experts on this subject based on the ideXlab platform.
-
outpatient erbium yag 2940 nm Laser Treatment for snoring a prospective study on 40 patients
Lasers in Medical Science, 2018Co-Authors: Isabelle Fini Storchi, Steven Parker, Francesca Bovis, Stefano Benedicenti, Andrea AmaroliAbstract:Snoring is a sleep phenomenon due to the partial upper airway obstruction during sleep which causes vibration of the tissues of the rhino-oro-hypopharynx and less frequently the larynx. This study evaluated the use and effectiveness of the erbium:YAG 2940-nm Laser as an adjunctive in providing Treatment for patients suffering from chronic snoring-related sleep disorders. A prospective study of 40 consecutive patients with snoring and sleep disorders was performed, assessing data before and after three Er:YAG Laser Treatment sessions. During Laser Treatment, the pain was almost absent. There were no side effects, except a very mild sore throat in 1 out of 40 patients. The patient's evaluation of satisfaction of the results obtained after the Treatments showed that 85% of cases were very satisfied, 5 patients (12.5%) reported being fairly satisfied with the Treatment and only 1 subject (2.5%) was not satisfied. Mallampati, Friedman Tongue Position, and degree of O (oropharynx) at nose oropharynx hypopharynx and larynx classification were significantly decreased after the Laser sessions. The decrease of Epworth Sleepiness Scale and Visual Analogue Scale for loudness of snoring, waking up during sleep because of snoring, dry mouth on waking, and choking was all statistically significant. The incidence of dreaming during the night also raised significantly; 30/40 (75%) of cases perceived less tightness in their throat and better breathing after Treatment. These results were stable at 20 months follow-up (14-24 q) in 72% of cases. Nonsurgical and non-invasive Er:YAG Laser Treatment demonstrated to be a valid procedure in reducing the loudness of snoring.
Michele Melia - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal ranibizumab for diabetic macular edema with prompt versus deferred Laser Treatment
Ophthalmology, 2012Co-Authors: M J Elman, Haijing Qin, Raj K Maturi, Adam R Glassman, Frederick L Ferris, Lloyd Paul Aiello, Neil M Bressler, Roy W Beck, Michele MeliaAbstract:Objective To report the 3-year follow-up results within a previously reported randomized trial evaluating prompt versus deferred (for ≥24 weeks) focal/grid Laser Treatment in eyes treated with intravitreal 0.5 mg ranibizumab for diabetic macular edema (DME). Design Multicenter, randomized clinical trial. Participants Three hundred sixty-one participants with visual acuity of 20/32 to 20/320 (approximate Snellen equivalent) and DME involving the fovea. Methods Ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and random assignment to prompt or deferred (≥24 weeks) focal/grid Laser Treatment. Main Outcome Measures Best-corrected visual acuity and safety at the 156-week (3-year) visit. Results The estimated mean change in visual acuity letter score from baseline through the 3-year visit was 2.9 letters more (9.7 vs. 6.8 letters; mean difference, 2.9 letters; 95% confidence interval, 0.4–5.4 letters; P = 0.02) in the deferral group compared with the prompt Laser Treatment group. In the prompt Laser Treatment group and deferral group, respectively, the percentage of eyes with a ≥10-letter gain/loss was 42% and 56% ( P = 0.02), whereas the respective percentage of eyes with a ≥10-letter gain/loss was 10% and 5% ( P = 0.12). Up to the 3-year visit, the median numbers of injections were 12 and 15 in the prompt and deferral groups, respectively ( P = 0.007), including 1 and 2 injections, respectively, from the 2-year up to the 3-year visit. At the 3-year visit, the percentages of eyes with central subfield thickness of 250 μm or more on time-domain optical coherence tomography were 36% in both groups ( P = 0.90). In the deferral group, 54% did not receive Laser Treatment during the trial. Systemic adverse events seemed to be similar in the 2 groups. Conclusions These 3-year results suggest that focal/grid Laser Treatment at the initiation of intravitreal ranibizumab is no better, and possibly worse, for vision outcomes than deferring Laser Treatment for 24 weeks or more in eyes with DME involving the fovea and with vision impairment. Some of the observed differences in visual acuity at 3 years may be related to fewer cumulative ranibizumab injections during follow-up in the prompt Laser Treatment group. Follow-up through 5 years continues. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references.
